The new report by Persistence Market Research (PMR) expects
the global gynaecological
cancer drugs market to witness significant growth, registering
6.2% CAGR during the forecast period. The global gynaecological cancer
drugs market is also expected to bring in US$ 41,855.8 million revenue
by the end of 2026.
Treatment of cancer is being increasingly focused on be
leading pharmaceutical companies, researchers, healthcare institutes and
governments of various countries. With increasing number of research and
development activities in cancer treatment, especially in gynaecological cancer
treatment, new treatments are reaching an increasing number of physicians
faster than ever.
Planning Forward? Access Sample Of Gynaecological
Cancer Drugs Market Report! https://www.persistencemarketresearch.com/samples/21700
Company Profiles
- Roche
Holdings AG
- AstraZeneca
- Sanofi
- Eli
Lilly & Co.
- Pfizer
Inc.
- Takeda
Pharmaceuticals CoLtd.
- Bristol-Myers
Squibb
- Merck
& Co.
- Dr
Reddy’s Laboratories
- Johnson
& Johnson (Alza Corporation)
- GlaxoSmithKline
(GSK)
How About Revitalizing The Strategy-Oriented
Funnel To Stay Ahead In The Gynaecological Cancer Drugs Market? https://www.persistencemarketresearch.com/methodology/21700
Also, availability of advanced treatment options and drugs has
resulted in the decline in cancer mortality rate across major developed
countries. However, the scenario is not same in the developing nations. This is
due to the high cost of cancer treatment and lack of availability of new
treatments.
New Treatment Options and Robust Pipeline of Drugs
in Clinical Development to Drive the Market Growth
According to the American Cancer Society, ovarian cancer ranks
fifth resulting in death among women, accounting for a maximum number of deaths
compared to any other cancer of female reproductive system. However, over the
past 20 years, the number of women diagnosed with ovarian cancer is decreasing.
This is due to the discovery of new drugs and treatments for treating
gynaecological cancer.
Increasing number of drugs have been approved by Food and
Drugs Administration (FDA) for gynaecological cancer. Meanwhile, a lot of drugs
developed by pharmaceutical firms are under clinical trials. Generic drugs are
also gaining traction in the gynaecological cancer drugs market.
Meanwhile, personalized medicine approach and targeted
therapies also present an opportunity for companies operating in the global
gynaecological cancer drugs market.
Planning To Introduce An Offbeat
Product/Technology In The Gynaecological Cancer Drugs Market? Go To “Purchase
Now” To Have Our Gynaecological Cancer Drugs Market Report! https://www.persistencemarketresearch.com/checkout/21700
Global Gynaecological Cancer Drugs Market- Segment-Wise
Analysis
The global gynaecological cancer drugs market is segmented
into distribution channels, indication, end users, drug class, and region.
Based on the drug class, the market is divided into antitumor antibiotic,
anthracyclines, plant alkaloid, alkylating agent, and other drug class.
Antitumor antibiotic is expected to grow at a faster phase any other drug
class. By the end of 2026, antitumor antibiotic is estimated to bring in more
than US$ 13,700 million revenue.
·
By end
users, the market segmentation includes specialized cancer
treatment centers, clinics, hospitals and others. Among these, hospitals are
expected to be the largest users of gynaecological cancer drugs. Hospitals are
estimated to exceed US$ 16,300 million revenue towards the end of 2026.
·
Based on
the indication, the market is further segmented into vaginal
cancer, vulvar cancer, ovarian & fallopian tube cancer, uterine cancer, and
cervical cancer. Uterine cancer is expected to account for the highest revenue
share. By the end of 2026, uterine cancer is estimated to exceed US$ 22,500
million revenue.
·
By
distribution channel, the market is divided into e-commerce, retail
pharmacies, and hospital pharmacies. Among these, hospital pharmacies are
expected to witness the highest growth during the forecast period. Hospital
pharmacies are estimated to bring in more than US$ 15,000 million revenue by
the end of the forecast period.
North America is expected to be one of the leading regions in
the global gynaecological cancer drugs market. Well-developed healthcare
infrastructure, presence of the major pharmaceutical companies, increasing
investment in the research and development of new drugs and therapies to treat
gynaecological cancer are some of the factors contributing to the growth of the
market in the region.
Read More Trending “PMR Exclusive Article”:
·
North
America Medical Wellness Devices Market
About Us:
Persistence Market Research is a
U.S.-based full-service market intelligence firm specializing in syndicated
research, custom research, and consulting services. Persistence Market Research
boasts market research expertise across the Healthcare, Chemicals and
Materials, Technology and Media, Energy and Mining, Food and Beverages,
Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation
industries. The company draws from its multi-disciplinary capabilities and
high-pedigree team of analysts to share data that precisely corresponds to
clients’ business needs.
Contact Us:
Address
– 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
Comments
Post a Comment